General Federal Contracts — February 24, 2026

$209M across two small biotech winners provides long-term funding visibility to 2036 with $98M outlayed.

$94M delivery order to veteran-owned firm via open competition underscores competitive edge despite low outlay.

$192M obligation with $0 outlay and expired 2020 period signals potential funding lapses.

Low outlays vs obligations: 0% (QLARANT), 11% (Veterans), 45-48% (BARDA pair), risking unmaterialized revenue.

Expired periods (3/4 contracts ended 2020) without extensions limit near-term cash flow.

$188M remaining BARDA options/outlays through 2036 for biodefense R&D.

Small/veteran-owned firms winning open competitions in HHS/VA ($378M total).

Follow-on potential for CMS data processing given historical engagement.

BARDA prioritizes small businesses for long-duration R&D ($209M, cost-plus-fixed-fee/cost-sharing).

VA/HHS favor vet-owned/small firms in open comp for exams/data ($269M).

{"entity"=>"MAPP Biopharmaceutical", "reason"=>"$189M options potential to 2036 in Marburg R&D.", "trigger"=>"option exercise >$110M obligated"}

{"entity"=>"The Medicines Company", "reason"=>"$54M remaining outlays to 2030 in anti-infectives.", "trigger"=>"outlay acceleration >50% total"}

{"entity"=>"Veterans Evaluation Services", "reason"=>"$84M un-outlayed in VA exams; vet-owned edge.", "trigger"=>"extension or new Region 4 award"}

{"entity"=>"QLARANT Integrity Solutions", "reason"=>"$192M inactive; CMS follow-on risk/opportunity.", "trigger"=>"re-award or outlay activity"}